Clinical Trial Update: Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GR-MD-02 for safety and efficacy in liver fibrosis with portal hypertension due to NASH cirrhosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis
• Nonalcoholic Steatohepatitis with Cirrhosis
• Portal Hypertension

Drugs mentioned

• GR-MD-02 (GR-MD-02)

Snippet

Sponsor: Galectin Therapeutics Inc. | Conditions: Hypertension, Portal | Phase 2 | Status: COMPLETED | Results posted: 2020-10-08